Platinum Partners Value Arbitrage Fund L.P. c/o Platinum PartnersInvestment Agreement • April 15th, 2015 • Echo Therapeutics, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
Contract Type FiledApril 15th, 2015 Company Industry JurisdictionThis Letter of Agreement, including the Exhibits attached hereto (collectively, this “Agreement”), sets forth the terms and conditions of the investment by certain investors (collectively, the “Investors”) in Echo Therapeutics, Inc. (the “Company”). In consideration of the good and valuable consideration, including the mutual covenants, agreements and promises set forth in this Agreement and elsewhere, the receipt and sufficiency of which are hereby acknowledged, each of the Investors and the Company hereto agree as follows.
Amendment to License, Development and Commercialization AgreementLicense, Development and Commercialization Agreement • April 15th, 2015 • Echo Therapeutics, Inc. • Electromedical & electrotherapeutic apparatus • New York
Contract Type FiledApril 15th, 2015 Company Industry JurisdictionThis Amendment to License, Development and Commercialization Agreement (this “Amendment”) is entered into as of the 29 day of December, 2014 (the “Amendment Date”) by and between Echo Therapeutics, Inc., having offices at 8 Penn Center, 1628 JFK Boulevard, Suite 300, Philadelphia, PA 19103 USA (“Echo”), and Medical Technologies Innovation Asia, Ltd., having registered offices at RM8, 17/F, Block B, Vigor Industrial Building, 14-20, Cheung Tat Road, Tsing Yi, Hong Kong (“MTIA”).
SECURITIES PURCHASE AGREEMENT BY AND BETWEEN THE INVESTORS LISTED ON THE SIGNATURE PAGES HERETO AND ECHO THERAPEUTICS, INC. DECEMBER 18, 2014Securities Purchase Agreement • April 15th, 2015 • Echo Therapeutics, Inc. • Electromedical & electrotherapeutic apparatus • New York
Contract Type FiledApril 15th, 2015 Company Industry JurisdictionTHIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December 18, 2014, is made by and between Echo Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Exhibit A hereto (collectively, the “Investors”).